Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects.

Gonzálbez J, Villabona C, Ramón J, Navarro MA, Giménez O, Ricart W, Soler J

Clinical endocrinology1 Aug 2000Cited by 58 (Europe PMC)

PMID10931101DOI10.1046/j.1365-2265.2000.01028.xPepBankPUB-10931101

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, cortisol at 30 minutes did not differ between high-dose and low-dose synacthen (684 +/- 123 versus 669 +/- 119 nmol/l).
In plain wordsIn healthy subjects, cortisol at 30 minutes did not differ between high-dose and low-dose synacthen.
Peptide
Cosyntropin
Outcome
No significant changeCortisol at 30 minutes by synacthen dose
Study
n = 30
Comparator
Low-dose synacthen 1 microgram
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol 30 min
684 nmol/l
high-dose test (250 microgram)
Plasma cortisol 30 min (+/- value)
123 nmol/l
high-dose test (250 microgram)
Plasma cortisol 30 min
669 nmol/l
low-dose test (1 microgram)
Plasma cortisol 30 min (+/- value)
119 nmol/l
low-dose test (1 microgram)
Source sentences
Summary
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110101
02HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, high-dose synacthen peak cortisol was 802 +/- 142 nmol/l and exceeded the low-dose peak (P < 0.001).
In plain wordsIn healthy subjects, peak cortisol was higher after high-dose synacthen than after low-dose synacthen.
Peptide
Cosyntropin
Outcome
IncreaseHigh-dose peak cortisol versus low-dose peak
Study
n = 30
Comparator
Low-dose synacthen peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol peak
802 nmol/l
high-dose test
Plasma cortisol peak (+/- value)
142 nmol/l
high-dose test
Plasma cortisol peak
691 nmol/l
low-dose test
Plasma cortisol peak (+/- value)
123 nmol/l
low-dose test
P
< 0.001
high-dose peak versus other tests
Source sentences
Summary
The only difference (P < 0.001) was found in the comparison of plasma cortisol peak reached with the HDT (802 +/- 142 nmol/l) with the other tests.
4 context sentences(design, population, supporting numbers)
Summary · context
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110105
03HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, the fifth percentile cortisol at 30 minutes after high-dose synacthen was 537 nmol/l.
In plain wordsIn healthy subjects, the fifth percentile cortisol at 30 minutes after high-dose synacthen was 537 nmol/l.
Peptide
Cosyntropin
Outcome
Not applicableHigh-dose fifth percentile at 30 minutes
Study
n = 30
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
5th percentile plasma cortisol at 30 min
537 nmol/l
high-dose test
Source sentences
Summary
Plasma cortisol levels obtained in the 5th percentile in each test were: at + 30 minutes: (HDT: 537, LDT: 489 nmol/l), peak: (HDT 649, LDT 498, ITT: 539 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110107
04HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, the fifth percentile cortisol at 30 minutes after low-dose synacthen was 489 nmol/l.
In plain wordsIn healthy subjects, the fifth percentile cortisol at 30 minutes after low-dose synacthen was 489 nmol/l.
Peptide
Cosyntropin
Outcome
Not applicableLow-dose fifth percentile at 30 minutes
Study
n = 30
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
5th percentile plasma cortisol at 30 min
489 nmol/l
low-dose test
Source sentences
Summary
Plasma cortisol levels obtained in the 5th percentile in each test were: at + 30 minutes: (HDT: 537, LDT: 489 nmol/l), peak: (HDT 649, LDT 498, ITT: 539 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110108
05HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, the fifth percentile peak cortisol after high-dose synacthen was 649 nmol/l.
In plain wordsIn healthy subjects, the fifth percentile peak cortisol after high-dose synacthen was 649 nmol/l.
Peptide
Cosyntropin
Outcome
Not applicableHigh-dose fifth percentile peak
Study
n = 30
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
5th percentile plasma cortisol peak
649 nmol/l
high-dose test
Source sentences
Summary
Plasma cortisol levels obtained in the 5th percentile in each test were: at + 30 minutes: (HDT: 537, LDT: 489 nmol/l), peak: (HDT 649, LDT 498, ITT: 539 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110109
06HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, the fifth percentile peak cortisol after low-dose synacthen was 498 nmol/l.
In plain wordsIn healthy subjects, the fifth percentile peak cortisol after low-dose synacthen was 498 nmol/l.
Peptide
Cosyntropin
Outcome
Not applicableLow-dose fifth percentile peak
Study
n = 30
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
5th percentile plasma cortisol peak
498 nmol/l
low-dose test
Source sentences
Summary
Plasma cortisol levels obtained in the 5th percentile in each test were: at + 30 minutes: (HDT: 537, LDT: 489 nmol/l), peak: (HDT 649, LDT 498, ITT: 539 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110110
07HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, high-dose synacthen cortisol at 30 minutes (684 +/- 123 nmol/l) did not differ from low-dose peak cortisol (691 +/- 123 nmol/l).
In plain wordsIn healthy subjects, cortisol 30 minutes after high-dose synacthen did not differ from peak cortisol after low-dose synacthen.
Peptide
Cosyntropin
Outcome
No significant changeHigh-dose 30-minute cortisol versus low-dose peak
Study
n = 30
Comparator
Low-dose synacthen peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol 30 min
684 nmol/l
high-dose test
Plasma cortisol 30 min (+/- value)
123 nmol/l
high-dose test
Plasma cortisol peak
691 nmol/l
low-dose test
Plasma cortisol peak (+/- value)
123 nmol/l
low-dose test
Source sentences
Summary
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110111
08HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, high-dose synacthen cortisol at 30 minutes (684 +/- 123 nmol/l) did not differ from the insulin tolerance test peak (673 +/- 99 nmol/l).
In plain wordsIn healthy subjects, high-dose synacthen cortisol at 30 minutes did not differ from the insulin tolerance test peak.
Peptide
Cosyntropin
Outcome
No significant changeHigh-dose 30-minute cortisol versus insulin test peak
Study
n: not reported in source
Comparator
Insulin tolerance test peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol 30 min
684 nmol/l
high-dose test
Plasma cortisol 30 min (+/- value)
123 nmol/l
high-dose test
Plasma cortisol peak
673 nmol/l
insulin tolerance test
Plasma cortisol peak (+/- value)
99 nmol/l
insulin tolerance test
Source sentences
Summary
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110102
09HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, low-dose synacthen cortisol at 30 minutes (669 +/- 119 nmol/l) did not differ from the insulin tolerance test peak (673 +/- 99 nmol/l).
In plain wordsIn healthy subjects, low-dose synacthen cortisol at 30 minutes did not differ from the insulin tolerance test peak.
Peptide
Cosyntropin
Outcome
No significant changeLow-dose 30-minute cortisol versus insulin test peak
Study
n: not reported in source
Comparator
Insulin tolerance test peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol 30 min
669 nmol/l
low-dose test
Plasma cortisol 30 min (+/- value)
119 nmol/l
low-dose test
Plasma cortisol peak
673 nmol/l
insulin tolerance test
Plasma cortisol peak (+/- value)
99 nmol/l
insulin tolerance test
Source sentences
Summary
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110103
10HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, low-dose synacthen peak cortisol (691 +/- 123 nmol/l) did not differ from the insulin tolerance test peak.
In plain wordsIn healthy subjects, peak cortisol after low-dose synacthen did not differ from the insulin tolerance test peak.
Peptide
Cosyntropin
Outcome
No significant changeLow-dose cortisol peak
Study
n: not reported in source
Comparator
Insulin tolerance test peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol peak
691 nmol/l
low-dose test
Plasma cortisol peak (+/- value)
123 nmol/l
low-dose test
Plasma cortisol peak
673 nmol/l
insulin tolerance test
Plasma cortisol peak (+/- value)
99 nmol/l
insulin tolerance test
Source sentences
Summary
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110104
11HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In healthy subjects, high-dose synacthen peak cortisol exceeded the insulin tolerance test peak (P < 0.001).
In plain wordsIn healthy subjects, peak cortisol was higher after high-dose synacthen than during the insulin tolerance test.
Peptide
Cosyntropin
Outcome
IncreaseHigh-dose peak cortisol versus insulin test
Study
n: not reported in source
Comparator
Insulin tolerance test peak
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Plasma cortisol peak
802 nmol/l
high-dose test
Plasma cortisol peak (+/- value)
142 nmol/l
high-dose test
Plasma cortisol peak
673 nmol/l
insulin tolerance test
Plasma cortisol peak (+/- value)
99 nmol/l
insulin tolerance test
P
< 0.001
high-dose peak versus other tests
Source sentences
Summary
The only difference (P < 0.001) was found in the comparison of plasma cortisol peak reached with the HDT (802 +/- 142 nmol/l) with the other tests.
4 context sentences(design, population, supporting numbers)
Summary · context
There were no differences between plasma cortisol 30 minutes after both short synacthen tests (HDT: 684 +/- 123, LDT: 669 +/- 119 nmol/l) and the peaks reached with the LDT (691 +/- 123 nmol/l) and the ITT (673 +/- 99 nmol/l).
Summary · context
The aim of this study was to compare the plasma cortisol response obtained with both short synacthen tests (high dose (HDT, 250 microgram) and low dose (LDT, 1 microgram)) with the peak reached during the ITT in healthy volunteers, and to establish the plasma cortisol cut-off level in each test.
Summary · context
Thirty healthy subjects (16 F, 14 M), mean age 34 years, underwent both short synacthen tests.
Summary · context
Twenty healthy subjects, 15 of whom (11 F, nine M) belonged to the above group, mean age 30 years, underwent an ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1093110106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.